Molex expands medical expertise through ProTek acquisition
“This strategic acquisition broadens the scope of our integrated medical solution offerings and significantly strengthens our medical device design, manufacturing, and test capabilities,” according to Tim Ruff, senior vice president of business development and corporate strategy, Molex.
“ProTek Medical Ltd. excels in cleanroom injection moulding and assembly, has an extensive metrology lab, and the quality and regulatory expertise that is critical to global medical device manufacturers.”
ProTek Medical Ltd. will continue to operate as a subsidiary of Molex Ireland Holdings, B.V. Its portfolio includes cardiac rhythm management components, infusion finished devices, and vascular delivery devices. The acquisition will further expand Molex’ European medical footprint.
Visit Molex at www.molex.com